Impact of simulated reduced injected dose on the assessment of amyloid PET scans
(2023) In European Journal of Nuclear Medicine and Molecular Imaging- Abstract
Purpose: To investigate the impact of reduced injected doses on the quantitative and qualitative assessment of the amyloid PET tracers [18F]flutemetamol and [18F]florbetaben. Methods: Cognitively impaired and unimpaired individuals (N = 250, 36% Aβ-positive) were included and injected with [18F]flutemetamol (N = 175) or [18F]florbetaben (N = 75). PET scans were acquired in list-mode (90–110 min post-injection) and reduced-dose images were simulated to generate images of 75, 50, 25, 12.5 and 5% of the original injected dose. Images were reconstructed using vendor-provided reconstruction tools and visually assessed for Aβ-pathology. SUVRs were calculated for a global cortical and three smaller... (More)
Purpose: To investigate the impact of reduced injected doses on the quantitative and qualitative assessment of the amyloid PET tracers [18F]flutemetamol and [18F]florbetaben. Methods: Cognitively impaired and unimpaired individuals (N = 250, 36% Aβ-positive) were included and injected with [18F]flutemetamol (N = 175) or [18F]florbetaben (N = 75). PET scans were acquired in list-mode (90–110 min post-injection) and reduced-dose images were simulated to generate images of 75, 50, 25, 12.5 and 5% of the original injected dose. Images were reconstructed using vendor-provided reconstruction tools and visually assessed for Aβ-pathology. SUVRs were calculated for a global cortical and three smaller regions using a cerebellar cortex reference tissue, and Centiloid was computed. Absolute and percentage differences in SUVR and CL were calculated between dose levels, and the ability to discriminate between Aβ- and Aβ + scans was evaluated using ROC analyses. Finally, intra-reader agreement between the reduced dose and 100% images was evaluated. Results: At 5% injected dose, change in SUVR was 3.72% and 3.12%, with absolute change in Centiloid 3.35CL and 4.62CL, for [18F]flutemetamol and [18F]florbetaben, respectively. At 12.5% injected dose, percentage change in SUVR and absolute change in Centiloid were < 1.5%. AUCs for discriminating Aβ- from Aβ + scans were high (AUC ≥ 0.94) across dose levels, and visual assessment showed intra-reader agreement of > 80% for both tracers. Conclusion: This proof-of-concept study showed that for both [18F]flutemetamol and [18F]florbetaben, adequate quantitative and qualitative assessments can be obtained at 12.5% of the original injected dose. However, decisions to reduce the injected dose should be made considering the specific clinical or research circumstances.
(Less)
- author
- organization
- publishing date
- 2023
- type
- Contribution to journal
- publication status
- epub
- subject
- keywords
- Alzheimer’s disease, Amyloid, Dose reduction, Neuroimaging, PET
- in
- European Journal of Nuclear Medicine and Molecular Imaging
- publisher
- Springer
- external identifiers
-
- pmid:37897616
- scopus:85175066219
- ISSN
- 1619-7070
- DOI
- 10.1007/s00259-023-06481-0
- language
- English
- LU publication?
- yes
- id
- f0b47f76-8de5-4789-857a-901a7990b76a
- date added to LUP
- 2023-12-18 12:15:05
- date last changed
- 2024-04-17 00:26:25
@article{f0b47f76-8de5-4789-857a-901a7990b76a,
abstract = {{<p>Purpose: To investigate the impact of reduced injected doses on the quantitative and qualitative assessment of the amyloid PET tracers [<sup>18</sup>F]flutemetamol and [<sup>18</sup>F]florbetaben. Methods: Cognitively impaired and unimpaired individuals (N = 250, 36% Aβ-positive) were included and injected with [<sup>18</sup>F]flutemetamol (N = 175) or [<sup>18</sup>F]florbetaben (N = 75). PET scans were acquired in list-mode (90–110 min post-injection) and reduced-dose images were simulated to generate images of 75, 50, 25, 12.5 and 5% of the original injected dose. Images were reconstructed using vendor-provided reconstruction tools and visually assessed for Aβ-pathology. SUVRs were calculated for a global cortical and three smaller regions using a cerebellar cortex reference tissue, and Centiloid was computed. Absolute and percentage differences in SUVR and CL were calculated between dose levels, and the ability to discriminate between Aβ- and Aβ + scans was evaluated using ROC analyses. Finally, intra-reader agreement between the reduced dose and 100% images was evaluated. Results: At 5% injected dose, change in SUVR was 3.72% and 3.12%, with absolute change in Centiloid 3.35CL and 4.62CL, for [<sup>18</sup>F]flutemetamol and [<sup>18</sup>F]florbetaben, respectively. At 12.5% injected dose, percentage change in SUVR and absolute change in Centiloid were < 1.5%. AUCs for discriminating Aβ- from Aβ + scans were high (AUC ≥ 0.94) across dose levels, and visual assessment showed intra-reader agreement of > 80% for both tracers. Conclusion: This proof-of-concept study showed that for both [<sup>18</sup>F]flutemetamol and [<sup>18</sup>F]florbetaben, adequate quantitative and qualitative assessments can be obtained at 12.5% of the original injected dose. However, decisions to reduce the injected dose should be made considering the specific clinical or research circumstances.</p>}},
author = {{Young, Peter and Heeman, Fiona and Axelsson, Jan and Collij, Lyduine E. and Hitzel, Anne and Sanaat, Amirhossein and Niñerola-Baizan, Aida and Perissinotti, Andrés and Lubberink, Mark and Frisoni, Giovanni B. and Zaidi, Habib and Barkhof, Frederik and Farrar, Gill and Baker, Suzanne and Gispert, Juan Domingo and Garibotto, Valentina and Rieckmann, Anna and Schöll, Michael}},
issn = {{1619-7070}},
keywords = {{Alzheimer’s disease; Amyloid; Dose reduction; Neuroimaging; PET}},
language = {{eng}},
publisher = {{Springer}},
series = {{European Journal of Nuclear Medicine and Molecular Imaging}},
title = {{Impact of simulated reduced injected dose on the assessment of amyloid PET scans}},
url = {{http://dx.doi.org/10.1007/s00259-023-06481-0}},
doi = {{10.1007/s00259-023-06481-0}},
year = {{2023}},
}